There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

The unusual move at FDA comes shortly after the agency's longtime vaccine chief was forced out over disagreements with Makary ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax WASHINGTON -- The Trump administration's effort to impose new ...

Full approval from the FDA means a product can stay on the market even after a health emergency ends. HealthDay News — Novavax’s COVID-19 vaccine could soon receive full approval from the US ...

CHICAGO, April 24 (Reuters) - Thousands of Americans campaigning for the Novavax (NVAX.O), opens new tab COVID-19 booster got some good news this week: the FDA signaled it might still win approval ...